Clinical effectiveness of dupilumab in CRSwNP: unaffected by baseline nasal polyp size in real-world settings
Our results suggests that dupilumab is effective in CRSwNP treatment, regardless of baseline nasal polyp size. Both small and large polyp groups showed significant improvements in NPS and patient-reported outcome measures. Future, prospective studies are warranted to validate these findings.
Authors
- P Kiss (ORCID: https://orcid.org/0000-0001-9187-2063)
- Clemens Holzmeister (ORCID: https://orcid.org/0000-0003-2835-5121)
- Michael Habenbacher
- Jakob Pock
- Alexandros Andrianakis (ORCID: https://orcid.org/0000-0002-2530-9931)
- Ulrich Moser (ORCID: https://orcid.org/0000-0002-2095-3453)
- Ahmed Abaira
- Angelika Lang
- Katharina Walla
Institutions
- Medical University of Graz (AT)
Publication Details
- Journal
- European Archives of Oto-Rhino-Laryngology
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1007/s00405-025-09275-2
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Medizinische Universität Graz